Idelalisib-associated colitis

Anna Sophie Weidner, Nicole C. Panarelli, Julia T. Geyer, Erica B. Bhavsar, Richard R. Furman, John P. Leonard, Jose Jessurun, Rhonda K. Yantiss

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Many patients develop gastrointestinal symptoms during idelalisib therapy; however, the pathologic effects of this drug have not been characterized. We identified 50 patients who received at least 3 months of idelalisib therapy. Clinical findings and symptoms were noted for each patient, and endoscopic findings were recorded for those who underwent colonoscopic examination. Hematoxylin and eosin-stained sections from colonic biopsy samples were evaluated for histologic patterns of injury. Twenty-three (46%) patients experienced diarrhea during treatment with idelalisib, including 8 with severe symptoms (≥7 stools/d above baseline and/or requiring hospitalization). Fourteen patients underwent colonoscopic examination with mucosal biopsy. Twelve (86%) of these had colitis characterized by intraepithelial lymphocytosis, crypt cell apoptosis, and neutrophilic infiltration of crypt epithelium. Eleven patients had symptoms severe enough to warrant drug withdrawal, including 9 who were also treated with corticosteroids. Idelalisib commonly causes diarrheal symptoms in patients undergoing therapy for B-cell neoplasia, which may be severe in nearly 20% of patients. Characteristic histologic features include the combination of intraepithelial lymphocytosis and crypt cell apoptosis, often accompanied by neutrophils. Discontinuation of the drug results in symptomatic improvement and resolution of histologic changes.

Original languageEnglish (US)
Pages (from-to)1661-1667
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume39
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Colitis
Lymphocytosis
B-Cell Chronic Lymphocytic Leukemia
Pharmaceutical Preparations
Apoptosis
Biopsy
Therapeutics
idelalisib
Hematoxylin
Eosine Yellowish-(YS)
Phosphatidylinositol 3-Kinases
Non-Hodgkin's Lymphoma
Diarrhea
Adrenal Cortex Hormones
Protein Isoforms
Hospitalization
Neutrophils
B-Lymphocytes
Epithelium
Wounds and Injuries

Keywords

  • CAL-101
  • chemotherapy
  • colitis
  • GS-1101
  • idelalisib
  • targeted therapy

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Weidner, A. S., Panarelli, N. C., Geyer, J. T., Bhavsar, E. B., Furman, R. R., Leonard, J. P., ... Yantiss, R. K. (2015). Idelalisib-associated colitis. American Journal of Surgical Pathology, 39(12), 1661-1667. https://doi.org/10.1097/PAS.0000000000000522

Idelalisib-associated colitis. / Weidner, Anna Sophie; Panarelli, Nicole C.; Geyer, Julia T.; Bhavsar, Erica B.; Furman, Richard R.; Leonard, John P.; Jessurun, Jose; Yantiss, Rhonda K.

In: American Journal of Surgical Pathology, Vol. 39, No. 12, 01.12.2015, p. 1661-1667.

Research output: Contribution to journalArticle

Weidner, AS, Panarelli, NC, Geyer, JT, Bhavsar, EB, Furman, RR, Leonard, JP, Jessurun, J & Yantiss, RK 2015, 'Idelalisib-associated colitis', American Journal of Surgical Pathology, vol. 39, no. 12, pp. 1661-1667. https://doi.org/10.1097/PAS.0000000000000522
Weidner AS, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP et al. Idelalisib-associated colitis. American Journal of Surgical Pathology. 2015 Dec 1;39(12):1661-1667. https://doi.org/10.1097/PAS.0000000000000522
Weidner, Anna Sophie ; Panarelli, Nicole C. ; Geyer, Julia T. ; Bhavsar, Erica B. ; Furman, Richard R. ; Leonard, John P. ; Jessurun, Jose ; Yantiss, Rhonda K. / Idelalisib-associated colitis. In: American Journal of Surgical Pathology. 2015 ; Vol. 39, No. 12. pp. 1661-1667.
@article{0a215dd894a04db98d984996644c3182,
title = "Idelalisib-associated colitis",
abstract = "Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Many patients develop gastrointestinal symptoms during idelalisib therapy; however, the pathologic effects of this drug have not been characterized. We identified 50 patients who received at least 3 months of idelalisib therapy. Clinical findings and symptoms were noted for each patient, and endoscopic findings were recorded for those who underwent colonoscopic examination. Hematoxylin and eosin-stained sections from colonic biopsy samples were evaluated for histologic patterns of injury. Twenty-three (46{\%}) patients experienced diarrhea during treatment with idelalisib, including 8 with severe symptoms (≥7 stools/d above baseline and/or requiring hospitalization). Fourteen patients underwent colonoscopic examination with mucosal biopsy. Twelve (86{\%}) of these had colitis characterized by intraepithelial lymphocytosis, crypt cell apoptosis, and neutrophilic infiltration of crypt epithelium. Eleven patients had symptoms severe enough to warrant drug withdrawal, including 9 who were also treated with corticosteroids. Idelalisib commonly causes diarrheal symptoms in patients undergoing therapy for B-cell neoplasia, which may be severe in nearly 20{\%} of patients. Characteristic histologic features include the combination of intraepithelial lymphocytosis and crypt cell apoptosis, often accompanied by neutrophils. Discontinuation of the drug results in symptomatic improvement and resolution of histologic changes.",
keywords = "CAL-101, chemotherapy, colitis, GS-1101, idelalisib, targeted therapy",
author = "Weidner, {Anna Sophie} and Panarelli, {Nicole C.} and Geyer, {Julia T.} and Bhavsar, {Erica B.} and Furman, {Richard R.} and Leonard, {John P.} and Jose Jessurun and Yantiss, {Rhonda K.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1097/PAS.0000000000000522",
language = "English (US)",
volume = "39",
pages = "1661--1667",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Idelalisib-associated colitis

AU - Weidner, Anna Sophie

AU - Panarelli, Nicole C.

AU - Geyer, Julia T.

AU - Bhavsar, Erica B.

AU - Furman, Richard R.

AU - Leonard, John P.

AU - Jessurun, Jose

AU - Yantiss, Rhonda K.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Many patients develop gastrointestinal symptoms during idelalisib therapy; however, the pathologic effects of this drug have not been characterized. We identified 50 patients who received at least 3 months of idelalisib therapy. Clinical findings and symptoms were noted for each patient, and endoscopic findings were recorded for those who underwent colonoscopic examination. Hematoxylin and eosin-stained sections from colonic biopsy samples were evaluated for histologic patterns of injury. Twenty-three (46%) patients experienced diarrhea during treatment with idelalisib, including 8 with severe symptoms (≥7 stools/d above baseline and/or requiring hospitalization). Fourteen patients underwent colonoscopic examination with mucosal biopsy. Twelve (86%) of these had colitis characterized by intraepithelial lymphocytosis, crypt cell apoptosis, and neutrophilic infiltration of crypt epithelium. Eleven patients had symptoms severe enough to warrant drug withdrawal, including 9 who were also treated with corticosteroids. Idelalisib commonly causes diarrheal symptoms in patients undergoing therapy for B-cell neoplasia, which may be severe in nearly 20% of patients. Characteristic histologic features include the combination of intraepithelial lymphocytosis and crypt cell apoptosis, often accompanied by neutrophils. Discontinuation of the drug results in symptomatic improvement and resolution of histologic changes.

AB - Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Many patients develop gastrointestinal symptoms during idelalisib therapy; however, the pathologic effects of this drug have not been characterized. We identified 50 patients who received at least 3 months of idelalisib therapy. Clinical findings and symptoms were noted for each patient, and endoscopic findings were recorded for those who underwent colonoscopic examination. Hematoxylin and eosin-stained sections from colonic biopsy samples were evaluated for histologic patterns of injury. Twenty-three (46%) patients experienced diarrhea during treatment with idelalisib, including 8 with severe symptoms (≥7 stools/d above baseline and/or requiring hospitalization). Fourteen patients underwent colonoscopic examination with mucosal biopsy. Twelve (86%) of these had colitis characterized by intraepithelial lymphocytosis, crypt cell apoptosis, and neutrophilic infiltration of crypt epithelium. Eleven patients had symptoms severe enough to warrant drug withdrawal, including 9 who were also treated with corticosteroids. Idelalisib commonly causes diarrheal symptoms in patients undergoing therapy for B-cell neoplasia, which may be severe in nearly 20% of patients. Characteristic histologic features include the combination of intraepithelial lymphocytosis and crypt cell apoptosis, often accompanied by neutrophils. Discontinuation of the drug results in symptomatic improvement and resolution of histologic changes.

KW - CAL-101

KW - chemotherapy

KW - colitis

KW - GS-1101

KW - idelalisib

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84948715031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948715031&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000522

DO - 10.1097/PAS.0000000000000522

M3 - Article

C2 - 26448188

AN - SCOPUS:84948715031

VL - 39

SP - 1661

EP - 1667

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 12

ER -